As the clinical use of SGLT2 inhibitors continues to expand, particularly among patients with heart failure and chronic kidney disease, emerging data from larger multinational cohorts are expected to provide deeper insights into their potential applicability within oncological settings. The gene discussed is SLC5A2; the disease is heart failure.